Skip to content
SEKISUI XenoTech DD Blog Logo

Month: April 2021

DDI & Drug Repurposing Article featured in Drug Discovery World (DDW) Spring Edition 2021

Repurposing (repositioning, re-profiling, or re-tasking) a drug potentially saves years of costly testing from going to waste and potentially providing a higher chance of success. “Perhaps most importantly, the risk of failure is lower […] because the repurposed drug has already been found to be sufficiently safe in preclinical models and humans if early-stage trials have been completed...

Improve the Value of Your Molecule's Testing with Expert Insight

Our expert team of DDI and drug metabolism consultants can help you piece together the data for a successful data package that meets regulatory expectations for thorough risk assessment of a new or repurposed compound

Read our Follow-Up Interview in Outsourcing Pharma

Find the Q&A between Director of Scientific Consulting, Dr. Maciej Czerwinski, and the editorial team at Outsourcing Pharma for more answers about how DDI testing and data interpretation adds value to the drug repurposing process

Human antibodies, including monoclonal and polyclonal, are used for inhibition and immunoblot applications